Benefits of Ferric Carboxymaltose Administration for Enhanced Hemoglobin Levels in Urban Population of Sindh: BOFERIN® Observational Study


  • Jahanara Ainuddin Department of Obstetrics & Gynecology, Dow University of Health Sciences, Karachi, Pakistan.
  • Nasreen Majid Department of Obstetrics & Gynecology, Memon Medical Institute, Karachi, Pakistan
  • Azra Aslam Department of Obstetrics & Gynecology, Shah Bhitai Government Hospital, Hyderabad, Pakistan.
  • Raheel Sikander Department of Obstetrics & Gynecology, Liaquat University of Health Sciences, Hyderabad, Pakistan.
  • Sarmad Iqbal Department of Pharmacy Practice, University of Karachi, Sindh, Pakistan.
  • Syed Saad Hussain Department of Pharmacy, Iqra University, Karachi, Pakistan.


Anemia, Iron-Deficiency, Iron carboxymaltose, Generic drugs, Hemoglobin, Ferric carboxymaltose


Background: Iron deficiency anemia is a major public health issue in developing countries, especially among women of reproductive age. Anemia is a major public health problem in women of reproductive age in rural Pakistan and a large proportion of women were found to have low levels of serum iron.
Materials and Methods: A multicenter observational cohort study was conducted at Karachi & Hyderabad from 8th February 2022 to 30th April 2022. Women with low hemoglobin level and age 18-45 years were included in this study. Patients were grouped according to 1-week assessment and 3-week assessment of hemoglobin concentration. A single dose of a generic substituent ferric carboxymaltose (Boferin®) was administered to the patients over 15 minutes infusion. Baseline hemoglobin levels were compared at 1 week and 3 weeks after administration of Ferric Carboxymaltose.
Results: A total of 104 patients were enrolled in this study. The mean hemoglobin levels at baseline were 9.22 ± 0.175 g/dl and 7.55 ± 0.329 g/ dl for 1-week and 3-week, respectively. The mean hemoglobin increases after 1 week and 3 week was reported as 1.4211± 0.169 g/dl (p< 0.001) and 2.321± 0.335 g/dl (p< 0.001) respectively. Only three patients presented with mild to moderate adverse effect which included abdominal discomfort and nausea.
Conclusion: This is a first in class study has shown statistically significant increase in hemoglobin at 1-week and 3-week interval with minimal side effects. It is concluded that Boferin® is efficacious in increasing hemoglobin levels in patients with iron deficiency anemia with its safety being documented in pregnant Pakistani population as well.




How to Cite

Ainuddin J, Majid N, Aslam A, Sikander R, Iqbal S, Hussain SS. Benefits of Ferric Carboxymaltose Administration for Enhanced Hemoglobin Levels in Urban Population of Sindh: BOFERIN® Observational Study. Nat J Health Sci [Internet]. 2023Jun.23 [cited 2024May29];8(2):62-6. Available from:



Research Article